Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guzman, M. L.
Right arrow Articles by Jordan, C. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guzman, M. L.
Right arrow Articles by Jordan, C. T.
Related Collections
Right arrow Neoplasia
Right arrow Plenary Papers
Right arrow Signal Transduction
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 October 2001, Vol. 98, No. 8, pp. 2301-2307

PLENARY PAPER

Nuclear factor-kappa B is constitutively activated in primitive human acute myelogenous leukemia cells

Monica L. Guzman, Sarah J. Neering, Donna Upchurch, Barry Grimes, Dianna S. Howard, David A. Rizzieri, Selina M. Luger, and Craig T. Jordan

From the Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology/Oncology, University of Kentucky Medical Center, Lexington; Division of Oncology and Bone Marrow Transplantation, Duke University Medical Center, Durham, NC; and Hematology-Oncology Division, University of Pennsylvania Medical Center, Philadelphia.

Human acute myelogenous leukemia (AML) is thought to arise from a rare population of malignant stem cells. Cells of this nature, herein referred to as leukemic stem cells (LSCs), have been documented for nearly all AML subtypes and appear to fulfill the criteria for stem cells in that they are self-renewing and give rise to the cells found in many leukemic populations. Because these cells are likely to be critical for the genesis and perpetuation of leukemic disease, the present studies sought to characterize unique molecular properties of the LSC population, with particular emphasis on the transcription factor, nuclear factor-kappa B (NF-kappa B). Previous experiments have shown that unstimulated human CD34+ progenitor cells do not express NF-kappa B. In contrast, primary AML CD34+ cells display readily detectable NF-kappa B activity as assessed by electrophoretic mobility shift assay and gene expression studies. Furthermore, detailed analyses of enriched AML stem cells (CD34+/CD38-/CD123+) indicate that NF-kappa B is also active in the LSC population. Given the expression of NF-kappa B in leukemic, but not normal primitive cells, the hypothesis that inhibition of NF-kappa B might induce leukemia-specific apoptosis was tested by treating primary cells with the proteasome inhibitor MG-132, a well-known inhibitor of NF-kappa B. Leukemic CD34+/CD38- cells displayed a rapid induction of cell death in response to MG-132, whereas normal CD34+/CD38- cells showed little if any effect. Taken together, these data indicate that primitive AML cells aberrantly express NF-kappa B and that the presence of this factor may provide unique opportunities to preferentially ablate LSCs.

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Exp. Med.Home page
M. Tang, X. Wei, Y. Guo, P. Breslin, S. Zhang, S. Zhang, W. Wei, Z. Xia, M. Diaz, S. Akira, et al.
TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice
J. Exp. Med., July 7, 2008; 205(7): 1611 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Hassane, M. L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J. L. Liesveld, M. Carroll, and C. T. Jordan
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
Blood, June 15, 2008; 111(12): 5654 - 5662.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. A. Huff and W. Matsui
Multiple Myeloma Cancer Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2895 - 2900.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. S. Hart and W. S. El-Deiry
Invincible, but Not Invisible: Imaging Approaches Toward In Vivo Detection of Cancer Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2901 - 2910.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Marcucci, M. D. Radmacher, K. Maharry, K. Mrozek, A. S. Ruppert, P. Paschka, T. Vukosavljevic, S. P. Whitman, C. D. Baldus, C. Langer, et al.
MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia
N. Engl. J. Med., May 1, 2008; 358(18): 1919 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Dayyani, J. Wang, J.-R. J. Yeh, E.-Y. Ahn, E. Tobey, D.-E. Zhang, I. D. Bernstein, R. T. Peterson, and D. A. Sweetser
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival
Blood, April 15, 2008; 111(8): 4338 - 4347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Liu, Z. Liu, Z. Xie, J. Pang, J. Yu, E. Lehmann, L. Huynh, T. Vukosavljevic, M. Takeki, R. B. Klisovic, et al.
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-{kappa}B-dependent DNA methyltransferase activity in acute myeloid leukemia
Blood, February 15, 2008; 111(4): 2364 - 2373.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. A. Duncan, C. A. Goetz, S. J. Stein, K. J. Mayo, B. J. Skaggs, K. Ziegelbauer, C. L. Sawyers, and A. S. Baldwin
I{kappa}B kinase {beta} inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells
Mol. Cancer Ther., February 1, 2008; 7(2): 391 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
G. Sethi, B. Sung, and B. B. Aggarwal
Nuclear Factor-{kappa}B Activation: From Bench to Bedside
Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Colado, S. Alvarez-Fernandez, P. Maiso, J. Martin-Sanchez, M. B. Vidriales, M. Garayoa, E. M. Ocio, J. C. Montero, A. Pandiella, and J. F. San Miguel
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
Haematologica, January 1, 2008; 93(1): 57 - 66.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. Guzman, X. Li, C. A. Corbett, R. M. Rossi, T. Bushnell, J. L. Liesveld, J. Hebert, F. Young, and C. T. Jordan
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
Blood, December 15, 2007; 110(13): 4436 - 4444.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. Guzman, R. M. Rossi, S. Neelakantan, X. Li, C. A. Corbett, D. C. Hassane, M. W. Becker, J. M. Bennett, E. Sullivan, J. L. Lachowicz, et al.
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
Blood, December 15, 2007; 110(13): 4427 - 4435.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Chumsri, W. Matsui, and A. M. Burger
Therapeutic Implications of Leukemic Stem Cell Pathways
Clin. Cancer Res., November 15, 2007; 13(22): 6549 - 6554.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
C. Naujokat and T. Saric
Concise Review: Role and Function of the Ubiquitin-Proteasome System in Mammalian Stem and Progenitor Cells
Stem Cells, October 1, 2007; 25(10): 2408 - 2418.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. van Rhenen, G. A. M. S. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. S.-v. Walsum, S. Zweegman, G. J. Ossenkoppele, and G. Jan Schuurhuis
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
Blood, October 1, 2007; 110(7): 2659 - 2666.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio
Nuclear factor {kappa}B as a target for new drug development in myeloid malignancies
Haematologica, September 1, 2007; 92(9): 1224 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Xiao, C. E. Inal, V. I. Parekh, C.-M. Chang, and M. H. Whitnall
5-Androstenediol Promotes Survival of {gamma}-Irradiated Human Hematopoietic Progenitors through Induction of Nuclear Factor-{kappa}B Activation and Granulocyte Colony-Stimulating Factor Expression
Mol. Pharmacol., August 1, 2007; 72(2): 370 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Rae, S. Langa, S. J. Tucker, and D. J. MacEwan
Elevated NF-{kappa}B responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis
PNAS, July 31, 2007; 104(31): 12790 - 12795.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Chakrabarti, P. Blair, and J. E. Freedman
CD40-40L Signaling in Vascular Inflammation
J. Biol. Chem., June 22, 2007; 282(25): 18307 - 18317.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Rizo, E. Vellenga, G. de Haan, and J. J. Schuringa
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R210 - R219.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. T. Jordan, M. L. Guzman, and M. Noble
Cancer stem cells.
N. Engl. J. Med., September 21, 2006; 355(12): 1253 - 1261.
[Full Text] [PDF]

Home page
 BloodHome page
T. Braun, G. Carvalho, A. Coquelle, M.-C. Vozenin, P. Lepelley, F. Hirsch, J.-J. Kiladjian, V. Ribrag, P. Fenaux, and G. Kroemer
NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
Blood, February 1, 2006; 107(3): 1156 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ravandi and Z. Estrov
Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia
Clin. Cancer Res., January 15, 2006; 12(2): 340 - 344.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
W. Stock
Controversies in Treatment of AML: Case-based Discussion
Hematology, January 1, 2006; 2006(1): 185 - 191.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. M. B. Kerbauy, V. Lesnikov, N. Abbasi, S. Seal, B. Scott, and H. J. Deeg
NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
Blood, December 1, 2005; 106(12): 3917 - 3925.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
I. Paz-Priel, D. H. Cai, D. Wang, J. Kowalski, A. Blackford, H. Liu, C. A. Heckman, A. F. Gombart, H. P. Koeffler, L. M. Boxer, et al.
CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) and C/EBP{alpha} Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-{kappa}B p50
Mol. Cancer Res., October 1, 2005; 3(10): 585 - 596.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. Guzman, R. M. Rossi, L. Karnischky, X. Li, D. R. Peterson, D. S. Howard, and C. T. Jordan
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
Blood, June 1, 2005; 105(11): 4163 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V. M.-D. Mas, D. Benzaquen, G. Laurent, F. Huguet, and B. Payrastre
Antileukemic activity of rapamycin in acute myeloid leukemia
Blood, March 15, 2005; 105(6): 2527 - 2534.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Frelin, V. Imbert, E. Griessinger, A.-C. Peyron, N. Rochet, P. Philip, C. Dageville, A. Sirvent, M. Hummelsberger, E. Berard, et al.
Targeting NF-{kappa}B activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells
Blood, January 15, 2005; 105(2): 804 - 811.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Platzer, A. Jorgl, S. Taschner, B. Hocher, and H. Strobl
RelB regulates human dendritic cell subset development by promoting monocyte intermediates
Blood, December 1, 2004; 104(12): 3655 - 3663.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. G. Gilliland, C. T. Jordan, and C. A. Felix
The Molecular Basis of Leukemia
Hematology, January 1, 2004; 2004(1): 80 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
I. Topisirovic, M. L. Guzman, M. J. McConnell, J. D. Licht, B. Culjkovic, S. J. Neering, C. T. Jordan, and K. L. B. Borden
Aberrant Eukaryotic Translation Initiation Factor 4E-Dependent mRNA Transport Impedes Hematopoietic Differentiation and Contributes to Leukemogenesis
Mol. Cell. Biol., December 15, 2003; 23(24): 8992 - 9002.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Yagi, A. Morimoto, M. Eguchi, S. Hibi, M. Sako, E. Ishii, S. Mizutani, S. Imashuku, M. Ohki, and H. Ichikawa
Identification of a gene expression signature associated with pediatric AML prognosis
Blood, September 1, 2003; 102(5): 1849 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Xu, S.-E. Simpson, T. J. Scialla, A. Bagg, and M. Carroll
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Blood, August 1, 2003; 102(3): 972 - 980.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Guan, B. Gerhard, and D. E. Hogge
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)
Blood, April 15, 2003; 101(8): 3142 - 3149.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. F. Holloway, S. Rao, X. Chen, and M. F. Shannon
Changes in Chromatin Accessibility Across the GM-CSF Promoter upon T Cell Activation Are Dependent on Nuclear Factor {kappa}B Proteins
J. Exp. Med., February 17, 2003; 197(4): 413 - 423.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hasegawa, K. Suzuki, C. Sakamoto, K. Ohta, S. Nishiki, M. Hino, N. Tatsumi, and S. Kitagawa
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia
Blood, February 1, 2003; 101(3): 1164 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. L. Guzman, C. F. Swiderski, D. S. Howard, B. A. Grimes, R. M. Rossi, S. J. Szilvassy, and C. T. Jordan
Preferential induction of apoptosis for primary human leukemic stem cells
PNAS, December 10, 2002; 99(25): 16220 - 16225.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii
Bay 11-7082 inhibits transcription factor NF-kappa B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells
Blood, August 13, 2002; 100(5): 1828 - 1834.
[Abstract] [Full Text]